Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
2021 · Journal of the National Comprehensive Cancer Network · 1,198 citations
https://doi.org/10.6004/jnccn.2021.0017
D
Dana B. Cardin
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
152
Papers
5.0K
Citations
27
h-index
49
i10-index
Dana B. Cardin is an academic researcher from Vanderbilt University. The author has contributed to research in topics: Colorectal Cancer Treatments and Studies & Pancreatic and Hepatic Oncology Research & Cancer Genomics and Diagnostics. The author has an h-index of 27, co-authored 130 publications.
ORCID: 0000-0002-0269-9615Papers by this author
worksA phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
2019 · Investigational New Drugs · 99 citations
https://doi.org/10.1007/s10637-019-00824-1
Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208.
2022 · Journal of Clinical Oncology · 11 citations
https://doi.org/10.1200/jco.2022.40.16_suppl.4136
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer
2025 · Nature Communications · 1 citations
https://doi.org/10.1038/s41467-025-63960-8
Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study
2024 · The Oncologist · 0 citations
https://doi.org/10.1093/oncolo/oyae210
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat